Drugs / UCB-6114
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04393298 | Jul 2020 → Apr 2024 | cancer | UCB Biopharma SRL | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCB-6114 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650523 ↗ |
| Known as | ginisortamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04393298 ↗ |
| Action | Inhibit | “In cell culture experiments, ginisortamab fully blocked the activity of recombinant human gremlin-1” PMID 38084840 ↗ Dec 2023 |
| Route | Intravenous | “Study participants will receive predefined doses of ginisortamab (UCB6114) administered intravenously at pre-specified time points.” NCT04393298 ↗ |